Pharmaceutical businesses moving goods between the UK and Singapore could eventually face fewer duplicated regulatory checks, following the launch of negotiations on a new agreement between the two countries.
Talks began on 22 September 2026 for a Mutual Recognition Agreement covering pharmaceutical good manufacturing practice, commonly known as GMP. The aim is to allow the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore’s Health Sciences Authority (HSA) to rely on each other’s relevant inspection results. That could reduce the time and administrative work involved when manufacturers supply both markets.
What could the agreement change?
GMP is the system of standards used to make sure medicines are consistently manufactured and controlled to the required quality. Manufacturers supplying another country may need to provide evidence that their facilities meet its requirements. Where regulators can rely on each other’s inspections, they need not repeat some of that work.
The proposed UK–Singapore agreement aims to simplify that process for businesses while maintaining regulatory standards. No agreement has been finalised yet, and the government has not confirmed which products or inspection processes its final terms would cover. Businesses should continue to follow the requirements currently in place.
Why does it matter for UK–Singapore trade?
Medicines are already an important part of trade between the two countries. The UK government says trade in medicinal and pharmaceutical products exceeded £300 million in 2025. The negotiations build on the UK–Singapore Free Trade Agreement and Digital Economy Agreement, as well as existing cooperation between the MHRA and HSA. Both regulators are members of the Access Consortium, which works to improve collaboration on medicines regulation.
For pharmaceutical businesses, the potential benefit is practical: less duplication in the regulatory process could make it easier and less costly to supply both markets. It is still too early to say exactly how much difference the agreement will make, or when any changes might take effect.
Support for pharmaceutical shipments
Regulatory developments are only one part of planning an international shipment. Pharmaceutical businesses also need reliable freight arrangements, clear documentation and a customs process that supports the movement of their goods.
Beckchoice has decades of experience supporting businesses in the pharmaceutical sector with their freight requirements. Our team can help you plan movements between the UK and Singapore, coordinate the shipping arrangements and support you with customs clearance through our in-house team.
If you have an upcoming shipment or are reviewing your supply chain, get in touch to discuss with our Beckchoice team.
Sources: UK government announcement and MHRA guidance on GMP.